Neuromuscular electrostimulation plus swallowing therapy may benefit dysphagia in severely disabled MS patients
This randomized controlled trial evaluated traditional swallowing therapy plus neuromuscular electrostimulation (TST-NMES) versus therapy plus sham stimulation (TST-S) in 101 people with multiple sclerosis and dysphagia. Both treatment groups showed improvement in dysphagia disturbances over time, though specific effect sizes and statistical measures were not reported. The study found significantly greater gains in ASHA scores among severely disabled patients (EDSS ≥7) who received NMES compared to sham. Baseline ASHA scores predicted outcomes, while EDSS influenced outcomes only in the control group.
Treatment safety and tolerability were confirmed, with no adverse effects reported during the study. Serious adverse events and discontinuation rates were not specified in the abstract.
Key limitations include the moderate sample size and lack of reported primary outcome, effect sizes, and confidence intervals. The main benefit was observed only in a severity subgroup (EDSS ≥7), and the abstract notes these results support further investigation in larger trials. For clinical practice, NMES combined with standard swallowing therapy appears feasible and may offer particular benefit for more disabled patients with MS-related dysphagia, though broader application requires additional evidence.